These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 36323770)

  • 1. Discovery of SARS-CoV-2 antiviral synergy between remdesivir and approved drugs in human lung cells.
    Nguyenla X; Wehri E; Van Dis E; Biering SB; Yamashiro LH; Zhu C; Stroumza J; Dugast-Darzacq C; Graham TGW; Wang X; Jockusch S; Tao C; Chien M; Xie W; Patel DJ; Meyer C; Garzia A; Tuschl T; Russo JJ; Ju J; Näär AM; Stanley S; Schaletzky J
    Sci Rep; 2022 Nov; 12(1):18506. PubMed ID: 36323770
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sofosbuvir terminated RNA is more resistant to SARS-CoV-2 proofreader than RNA terminated by Remdesivir.
    Jockusch S; Tao C; Li X; Chien M; Kumar S; Morozova I; Kalachikov S; Russo JJ; Ju J
    Sci Rep; 2020 Oct; 10(1):16577. PubMed ID: 33024223
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatitis C Virus Protease Inhibitors Show Differential Efficacy and Interactions with Remdesivir for Treatment of SARS-CoV-2
    Gammeltoft KA; Zhou Y; Duarte Hernandez CR; Galli A; Offersgaard A; Costa R; Pham LV; Fahnøe U; Feng S; Scheel TKH; Ramirez S; Bukh J; Gottwein JM
    Antimicrob Agents Chemother; 2021 Aug; 65(9):e0268020. PubMed ID: 34097489
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatitis C virus drugs that inhibit SARS-CoV-2 papain-like protease synergize with remdesivir to suppress viral replication in cell culture.
    Bafna K; White K; Harish B; Rosales R; Ramelot TA; Acton TB; Moreno E; Kehrer T; Miorin L; Royer CA; García-Sastre A; Krug RM; Montelione GT
    Cell Rep; 2021 May; 35(7):109133. PubMed ID: 33984267
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The FDA-Approved Drug Cobicistat Synergizes with Remdesivir To Inhibit SARS-CoV-2 Replication
    Shytaj IL; Fares M; Gallucci L; Lucic B; Tolba MM; Zimmermann L; Adler JM; Xing N; Bushe J; Gruber AD; Ambiel I; Taha Ayoub A; Cortese M; Neufeldt CJ; Stolp B; Sobhy MH; Fathy M; Zhao M; Laketa V; Diaz RS; Sutton RE; Chlanda P; Boulant S; Bartenschlager R; Stanifer ML; Fackler OT; Trimpert J; Savarino A; Lusic M
    mBio; 2022 Apr; 13(2):e0370521. PubMed ID: 35229634
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The anti-HCV, Sofosbuvir, versus the anti-EBOV Remdesivir against SARS-CoV-2 RNA dependent RNA polymerase in silico.
    Elfiky AA; Azzam EB; Shafaa MW
    Mol Divers; 2022 Feb; 26(1):171-181. PubMed ID: 33389441
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Broad-Spectrum
    Lo MK; Shrivastava-Ranjan P; Chatterjee P; Flint M; Beadle JR; Valiaeva N; Murphy J; Schooley RT; Hostetler KY; Montgomery JM; Spiropoulou CF
    Microbiol Spectr; 2021 Dec; 9(3):e0153721. PubMed ID: 34817209
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimization of the Prodrug Moiety of Remdesivir to Improve Lung Exposure/Selectivity and Enhance Anti-SARS-CoV-2 Activity.
    Hu H; Mady Traore MD; Li R; Yuan H; He M; Wen B; Gao W; Jonsson CB; Fitzpatrick EA; Sun D
    J Med Chem; 2022 Sep; 65(18):12044-12054. PubMed ID: 36070561
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency.
    Gordon CJ; Tchesnokov EP; Woolner E; Perry JK; Feng JY; Porter DP; Götte M
    J Biol Chem; 2020 May; 295(20):6785-6797. PubMed ID: 32284326
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rethinking Remdesivir: Synthesis, Antiviral Activity, and Pharmacokinetics of Oral Lipid Prodrugs.
    Schooley RT; Carlin AF; Beadle JR; Valiaeva N; Zhang XQ; Clark AE; McMillan RE; Leibel SL; McVicar RN; Xie J; Garretson AF; Smith VI; Murphy J; Hostetler KY
    Antimicrob Agents Chemother; 2021 Sep; 65(10):e0115521. PubMed ID: 34310217
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug synergy of combinatory treatment with remdesivir and the repurposed drugs fluoxetine and itraconazole effectively impairs SARS-CoV-2 infection in vitro.
    Schloer S; Brunotte L; Mecate-Zambrano A; Zheng S; Tang J; Ludwig S; Rescher U
    Br J Pharmacol; 2021 Jun; 178(11):2339-2350. PubMed ID: 33825201
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Remdesivir against COVID-19 and Other Viral Diseases.
    Malin JJ; Suárez I; Priesner V; Fätkenheuer G; Rybniker J
    Clin Microbiol Rev; 2020 Dec; 34(1):. PubMed ID: 33055231
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Why Remdesivir Failed: Preclinical Assumptions Overestimate the Clinical Efficacy of Remdesivir for COVID-19 and Ebola.
    Yan VC; Muller FL
    Antimicrob Agents Chemother; 2021 Sep; 65(10):e0111721. PubMed ID: 34252308
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The development of broad-spectrum antiviral medical countermeasures to treat viral hemorrhagic fevers caused by natural or weaponized virus infections.
    Hickman MR; Saunders DL; Bigger CA; Kane CD; Iversen PL
    PLoS Negl Trop Dis; 2022 Mar; 16(3):e0010220. PubMed ID: 35259154
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of Antivirals in SARS-CoV-2 Infection. Critical Review of the Role of Remdesivir.
    Moreno S; Alcázar B; Dueñas C; González Del Castillo J; Olalla J; Antela A
    Drug Des Devel Ther; 2022; 16():827-841. PubMed ID: 35370401
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pyrimidine inhibitors synergize with nucleoside analogues to block SARS-CoV-2.
    Schultz DC; Johnson RM; Ayyanathan K; Miller J; Whig K; Kamalia B; Dittmar M; Weston S; Hammond HL; Dillen C; Ardanuy J; Taylor L; Lee JS; Li M; Lee E; Shoffler C; Petucci C; Constant S; Ferrer M; Thaiss CA; Frieman MB; Cherry S
    Nature; 2022 Apr; 604(7904):134-140. PubMed ID: 35130559
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of Antiviral Activity of Gemcitabine with 2'-Fluoro-2'-Deoxycytidine and Combination Therapy with Remdesivir against SARS-CoV-2.
    Jang Y; Shin JS; Lee MK; Jung E; An T; Kim UI; Kim K; Kim M
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33557278
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Beneficial effect of combinational methylprednisolone and remdesivir in hamster model of SARS-CoV-2 infection.
    Ye ZW; Yuan S; Chan JF; Zhang AJ; Yu CY; Ong CP; Yang D; Chan CC; Tang K; Cao J; Poon VK; Chan CC; Cai JP; Chu H; Yuen KY; Jin DY
    Emerg Microbes Infect; 2021 Dec; 10(1):291-304. PubMed ID: 33538646
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent knowledge in favor of remdesivir (GS-5734) as a therapeutic option for the COVID-19 infections.
    Saqrane S; El Mhammedi MA; Lahrich S; Laghrib F; El Bouabi Y; Farahi A; Bakasse M
    J Infect Public Health; 2021 May; 14(5):655-660. PubMed ID: 33857725
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The NSP14/NSP10 RNA repair complex as a Pan-coronavirus therapeutic target.
    Rona G; Zeke A; Miwatani-Minter B; de Vries M; Kaur R; Schinlever A; Garcia SF; Goldberg HV; Wang H; Hinds TR; Bailly F; Zheng N; Cotelle P; Desmaële D; Landau NR; Dittmann M; Pagano M
    Cell Death Differ; 2022 Feb; 29(2):285-292. PubMed ID: 34862481
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.